Verified
After several months, stair climbing remained easier than before treatment. Increased appetite was the hardest part, so the paediatric team monitored weight and meal portions closely.
24 Oct 2026
Deflazacort
Quality products
24/7 Support
Fast delivery
Delivery
from 4 days
Active ingredient
Deflazacort
Deflazacort is an oral corticosteroid for people with Duchenne muscular dystrophy and selected inflammatory or autoimmune disorders. It helps preserve muscle function and control disease-related inflammation by modifying immune activity.
Description
Deflazacort is an oral glucocorticoid used mainly for Duchenne muscular dystrophy and selected inflammatory or autoimmune disorders. It belongs to the corticosteroid class and reduces inflammation and modifies immune activity.
Composition
Deflazacort is an oral corticosteroid with anti-inflammatory and immunosuppressive activity. It is used mainly for Duchenne muscular dystrophy and may be prescribed for selected inflammatory or autoimmune disorders. The exact strength, ingredients, and formulation details are stated on the pack.
Dosage and usage
The precise dose depends on the diagnosis, age, body weight, treatment duration, and response. DMD regimens are weight-based, while inflammatory conditions may require an initial dose followed by gradual reduction. A prescriber selects the regimen and adjusts it during follow-up.
- Take the tablets by mouth at the prescribed frequency.
- Use the same time of day consistently when possible.
- Swallow the tablet with water unless the prescriber gives different instructions.
- Take it with food if it causes stomach discomfort.
- Do not change the dose because symptoms improve or worsen.
- If a dose is missed, take it when remembered unless the next scheduled dose is near; do not double the next dose.
- A prolonged course requires a planned reduction rather than sudden withdrawal.
The treatment period may range from a short course for an inflammatory flare to long-term therapy in DMD. Children receiving long-term treatment need assessment of growth, weight, blood pressure, glucose, bone health, cataracts, infection history, and functional status.
Keep a written record of the daily dose and any planned dose changes. This is useful when treatment involves several specialists, especially neurology, rheumatology, paediatrics, or respiratory medicine.
How it works
Deflazacort is an oxazoline derivative related to prednisolone. After oral absorption, it is converted into the active metabolite deflazacort-21-hydroxide. This metabolite binds to intracellular glucocorticoid receptors, moves into the cell nucleus, and changes the transcription of genes involved in inflammation and immune regulation.
The result is lower production of several inflammatory mediators, reduced movement of immune cells into damaged tissue, and less release of substances that promote swelling and pain. Corticosteroids imitate hormones produced naturally by the adrenal glands, although pharmacological doses produce stronger and longer-lasting effects than normal daily hormone secretion.
The mechanism explains both the benefits and limitations of treatment. Suppressing inflammatory activity can protect muscle and reduce tissue injury, while the same immune effects can make infections harder to recognise and may impair wound healing. Long-term exposure also affects bone turnover, glucose regulation, appetite, skin, and the hypothalamic-pituitary-adrenal axis. Monitoring is therefore part of treatment, not an optional add-on. The balance between symptom control and toxicity changes with dose and duration.
Deflazacort is not a fast painkiller. Its clinical value comes from reducing an underlying inflammatory or immune process over time.
Indications
Deflazacort is a corticosteroid with anti-inflammatory and immunosuppressive activity. Its best-established use is Duchenne muscular dystrophy (DMD), a genetic muscle-wasting condition in which long-term glucocorticoid treatment can help preserve ambulation, upper-limb function, and respiratory strength. The United States Food and Drug Administration approved deflazacort for patients with DMD aged 2 years and older in 2017.[1]
Doctors may also use deflazacort in selected inflammatory or autoimmune conditions when suppression of excessive immune activity is clinically necessary. These may include rheumatoid arthritis, systemic lupus erythematosus, polymyalgia rheumatica, sarcoidosis, juvenile idiopathic arthritis, and other muscular dystrophies. The choice depends on the diagnosis, disease severity, previous corticosteroid response, age, body weight, and the risks of prolonged steroid exposure.
Role in Duchenne Muscular Dystrophy Management
In DMD, glucocorticoid therapy is intended to slow the loss of muscle strength rather than reverse the underlying genetic disorder. Maintaining mobility can delay the loss of functional milestones such as climbing stairs, rising from the floor, and lifting the arms overhead. Preserving respiratory and cardiac muscle function also forms part of long-term neuromuscular care.
A useful clinical detail is that treatment goals in paediatric neurology are measured in function, not just muscle size. A child who remains able to stand from the floor or walk independently for longer may be gaining a meaningful benefit, even when day-to-day changes seem small.
The 2018 DMD care guidelines published in The Lancet Neurology describe corticosteroids as a central part of multidisciplinary DMD management, alongside physiotherapy, respiratory surveillance, cardiac assessment, nutrition, and orthopaedic care.[2]
Application in Autoimmune and Inflammatory Disorders
Deflazacort can reduce inflammatory signalling in diseases where immune activity damages joints, muscles, lungs, skin, or other tissues. Rheumatoid arthritis may involve persistent joint inflammation, while systemic lupus erythematosus can affect several organs. Sarcoidosis may cause inflammatory granulomas, and polymyalgia rheumatica produces pain and stiffness around the shoulders and hips.
Use in juvenile idiopathic arthritis requires special attention to growth, bone health, infection risk, and the need for steroid-sparing treatment. A corticosteroid may control a flare while a longer-term disease-modifying therapy takes effect. It should not be treated as a universal replacement for disease-specific therapy.
Comparison
Deflazacort, prednisone, prednisolone, methylprednisolone, dexamethasone, and betamethasone all act through glucocorticoid receptors. They differ in potency, duration, mineralocorticoid activity, formulation, and how clinicians balance disease control against adverse effects.
| Corticosteroid | Clinical profile | Main limitation |
|---|---|---|
| Deflazacort | Used in DMD and selected inflammatory disorders; often considered when a weight, growth, or metabolic profile is part of the treatment decision | Can still cause adrenal suppression, bone effects, cataracts, infection risk, and mood changes |
| Prednisone or prednisolone | Familiar systemic corticosteroids with broad inflammatory indications and extensive clinical experience | Weight gain, appetite increase, glucose changes, and skeletal complications may be troublesome during prolonged treatment |
| Methylprednisolone | Available in oral and injectable forms; commonly selected when a stronger anti-inflammatory effect or hospital-based treatment is needed | Systemic steroid complications remain possible, especially with repeated or prolonged exposure |
Corticosteroid equivalence is not a simple milligram-for-milligram conversion. Deflazacort and prednisolone have different pharmacokinetic properties, so a switch requires a clinician’s conversion plan. Dexamethasone and betamethasone are longer-acting options that may produce more persistent adrenal suppression, while methylprednisolone is often chosen for specific acute or hospital-based circumstances.
A physician may select deflazacort when its established role in DMD fits the patient’s treatment goals or when the expected adverse-effect profile is preferable to another glucocorticoid. The choice still depends on individual response. No corticosteroid eliminates the risks of long-term systemic steroid therapy.
Contraindications
Deflazacort is not suitable for everyone. A prescriber needs a complete medical history before starting or continuing treatment.
Deflazacort can interact with strong CYP3A4 inhibitors such as clarithromycin, erythromycin, ketoconazole, itraconazole, and some HIV medicines. These combinations may raise deflazacort exposure and increase steroid toxicity. CYP3A4 inducers such as rifampicin, carbamazepine, phenytoin, and phenobarbital may reduce exposure and alter disease control.
Non-steroidal anti-inflammatory drugs can add to gastrointestinal ulcer or bleeding risk. Diuretics and medicines that lower potassium may increase electrolyte problems. Diabetes medicines may require adjustment because corticosteroids can raise blood glucose.
Pregnancy and breastfeeding require an individual risk assessment. The benefits of controlling severe inflammation may outweigh potential risks, but prolonged systemic corticosteroid exposure needs specialist oversight.
When this is not for you
This medication is not for you if
- You have had a serious allergic reaction to deflazacort or an ingredient in the tablets.
- You have an untreated systemic fungal infection.
- You are taking medicines that strongly affect CYP3A4 activity without a planned interaction review.
- You have an active infection that requires treatment and the prescriber has not assessed the steroid risk.
- You have severe uncontrolled diabetes, uncontrolled hypertension, active peptic ulcer disease, severe osteoporosis, or serious psychiatric illness requiring a different treatment plan.
- You have recently received, or are due to receive, a live vaccine and the corticosteroid dose creates an immunosuppression concern.
Extra care is needed with tuberculosis exposure, strongyloidiasis risk, measles or chickenpox exposure, glaucoma, cataracts, heart failure, kidney disease, liver disease, epilepsy, osteoporosis, and a history of steroid-related mood changes.
Side effects
Side effects depend on dose, treatment duration, age, infection exposure, and individual susceptibility. Short-term effects may include increased appetite, stomach upset, difficulty sleeping, irritability, mood changes, acne, facial fullness, and temporary increases in blood pressure or blood glucose.
Longer treatment can increase the risk of:
- Weight gain and changes in body fat distribution
- High blood pressure and glucose intolerance
- Reduced bone mineral density and corticosteroid-induced osteoporosis
- Growth slowing in children
- Cataracts or raised intraocular pressure
- Skin thinning, easy bruising, and delayed wound healing
- Menstrual changes or other endocrine effects
- Adrenal suppression
- Increased susceptibility to infection
- Mood disturbance, anxiety, or rarely severe psychiatric symptoms
Deflazacort may be associated with less weight gain than prednisone in some DMD studies, yet it remains a systemic corticosteroid. The difference is not large enough to remove the need for weight, glucose, blood pressure, and bone monitoring.
A child receiving treatment may grow more slowly even while muscle function is preserved. These two outcomes need to be assessed separately rather than assuming that maintained walking means every aspect of treatment is problem-free.
Cataracts can develop gradually. Blurred vision, glare, difficulty reading, or new eye discomfort deserves prompt assessment, especially during long-term therapy.
Tell the treating team about fever, persistent cough, chickenpox exposure, painful urination, or a wound that is not healing. Corticosteroids can reduce visible inflammation and make an infection appear less obvious.
Vaccination planning also matters. Live vaccines may be unsuitable during immunosuppressive corticosteroid treatment, depending on the dose and duration. Inactivated vaccines may produce a weaker immune response, so timing should be coordinated with the medical team.
Common mistakes
Several avoidable problems can reduce treatment benefit or increase risk:
- Stopping after a few weeks because symptoms have improved.
- Doubling a missed dose.
- Taking extra tablets during a flare without a prescribed plan.
- Forgetting to mention deflazacort before surgery, emergency treatment, or hospital admission.
- Treating fever as minor because the steroid reduces the usual inflammatory response.
- Missing eye, bone, blood pressure, growth, or glucose monitoring.
- Receiving a live vaccine without confirming whether the current steroid regimen permits it.
- Taking ibuprofen or another NSAID frequently without considering gastrointestinal risk.
- Failing to report major mood changes, severe insomnia, or unusual behaviour.
- Switching between deflazacort and another steroid without an organised conversion and taper.
Carry the medication name and current regimen in your phone’s medical information. Emergency clinicians need to know about long-term corticosteroid exposure before surgery or treatment for severe infection.
Tablets should be taken exactly as prescribed. Crushing or mixing a tablet should only be done when the prescriber or pharmacist has confirmed that the specific tablet can be handled that way.
What doctors say
In clinical practice, doctors usually judge deflazacort by function, disease control, and cumulative toxicity. For DMD, useful measures may include walking ability, timed motor tasks, respiratory tests, cardiac surveillance, weight, growth, and bone health.
A neurologist may explain that consistency matters because irregular steroid exposure can produce fluctuating disease control and complicate adrenal recovery. A rheumatologist may use the lowest dose that controls inflammation while introducing or maintaining a steroid-sparing treatment where appropriate.
The most practical prescribing principle is to separate disease benefit from side-effect monitoring. A patient can have preserved muscle function and still develop high blood pressure, cataracts, low bone density, or glucose problems. Regular review helps identify these changes before they become disabling.
Frequently asked questions
What is Deflazacort used for?
Deflazacort is a glucocorticoid used for Duchenne muscular dystrophy and selected inflammatory or autoimmune disorders. The FDA approved it for DMD in patients aged 2 years and older in 2017. Treatment aims to reduce abnormal inflammation or preserve muscle function, depending on the diagnosis.
How does Deflazacort work?
Deflazacort is converted to deflazacort-21-hydroxide, which activates glucocorticoid receptors inside cells. This changes gene activity and reduces inflammatory and immune signalling. The WHO’s 2021 essential medicines information describes corticosteroids as medicines that can suppress inflammation and immune responses, although their systemic effects require monitoring.
Can Deflazacort be stopped suddenly?
Sudden withdrawal after sustained treatment can cause adrenal insufficiency because the body may temporarily produce too little cortisol. Symptoms can include marked weakness, vomiting, dizziness, low blood pressure, and collapse. The FDA’s 2017 prescribing information supports gradual dose reduction when clinically appropriate rather than abrupt discontinuation.
Does Deflazacort cause weight gain?
Weight gain and increased appetite can occur, especially during prolonged treatment. Some DMD research has found less weight gain with deflazacort than with prednisone, but the difference varies between patients. The 2016 Neurology trial comparing deflazacort and prednisone supports monitoring weight, growth, behaviour, and other steroid effects during treatment.
Can Deflazacort affect children’s growth?
Long-term corticosteroid treatment can slow linear growth, even when it helps preserve muscle function. Paediatric monitoring should include height, weight, puberty, bone health, and functional progress. The 2018 DMD care recommendations in The Lancet Neurology treat growth and skeletal surveillance as part of ongoing corticosteroid management.
What infections are important during treatment?
Deflazacort can reduce immune activity and may make infections harder to recognise. Fever, persistent cough, breathing difficulty, painful urination, unusual weakness, or exposure to chickenpox or measles requires prompt medical attention. The FDA’s 2017 prescribing information and MOHAP guidance support reviewing infection risk before immunosuppressive treatment and before live vaccination.
Does Deflazacort interact with other medicines?
Yes. Strong CYP3A4 inhibitors, CYP3A4 inducers, NSAIDs, diuretics, diabetes medicines, anticoagulants, and some vaccines may affect treatment safety or response. A medication review is needed before combining these treatments. The FDA’s 2017 prescribing information identifies interaction risks that can increase corticosteroid exposure or reduce its clinical effect.
Do you offer anonymous delivery?
Your order will be securely packed and shipped within 24 hours. This is exactly what your package will look like (images of an actual item sent). It has the size and look of a regular private letter (24x11x0.7 cm) and its contents cannot be seen.
Deflazacort: Reviews and Experiences
3.5
Based on 4 reviews
Verified
Joint stiffness improved during the first week. Sleep was lighter, and I needed to take the tablet earlier in the day rather than at bedtime.
27 Sep 2026
Verified
Walking endurance seemed steadier after the dose plan was established. Growth slowed for a period, which led to more frequent paediatric reviews.
13 Oct 2026
Verified
The inflammation settled, but appetite and mood changed during the course. A planned taper helped avoid the sudden stop that I had initially considered.
3 Oct 2026
Sources
- U.S. Food and Drug Administration (2017). EMFLAZA (deflazacort) Prescribing Information.
- The Lancet Neurology (2018). Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional management.
